Leibniz Prize awarded to RNA researcher
IMIB
The news caught him by surprise: Jörg Vogel was busy preparing an urgent grant proposal he wants to submit with Deutsche Forschungsgemeinschaft (DFG). Just at this moment, an e-mail from the DFG arrived in his inbox, informing him that he would receive one of the Gottfried Wilhelm Leibniz Prizes 2017 worth 2.5 million euros.
"I was flabbergasted," recalls the Würzburg professor for infection biology who was in Greifswald when he learned about the good news. On Thursday afternoon he held two lectures there: one at the university and the other at the Alfried Krupp Wissenschaftskolleg. So there where probably enough people present to congratulate him after the news of his top-notch recognition had made the rounds.
Since 2009, Professor Vogel has been the director of the Institute for Molecular Infection Biology (IMIB) of the Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany, and spokesman of the Research Center for Infectious Diseases (ZINF). Moreover, he is the founding director of the Helmholtz Institute for RNA-based Infection Research (HIRI) which the Helmholtz Association will establish at the JMU.
Vogel's research focuses on bacteria
The Leibniz laureate studies small regulatory RNA molecules of bacterial pathogens such as salmonella. He and his team are determined to get to the bottom of how these molecules work and act. His work could show new ways to fight pathogens.
"With Jörg Vogel, the award recognizes one of the world's leading researchers in the field of RNA biology," as a DFG press release puts it, stating further that he is given the prize for his seminal contribution to understanding regulatory RNA molecules in infection biology. According to the DFG, Vogel detected the importance of RNA biochemistry very early on. Moreover, he has done pioneering work in the field of RNA analysis with the application and development of high-throughput sequencing methods.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.